AZD 0837

Drug Profile

AZD 0837

Alternative Names: AR-H067637; AZD0837

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Class Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Thromboembolism

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 Jul 2010 Discontinued - Phase-II for Thromboembolism in European Union (PO)
  • 14 Nov 2009 Adverse events and pharmacodynamics data from a phase II trial (NCT00623779) in Thromboembolism prevention presented at the the 82nd Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top